Quick orientationEvidence update: 6 October 2026
What is Semaglutide?
Semaglutide is a GLP-1 receptor agonist. It mimics one of the body's meal-related signals and changes both appetite and glucose regulation.
Why people are interested
The potential benefits, unpacked.
Here are the goals and claims that bring readers to this guide. The evidence note shows which part is demonstrated, early research or still a question.
The headline interest
Large randomised trials support diabetes and weight-management indications with specific licensed products.
What the mechanism suggests
GLP-1 receptor agonist that slows gastric emptying, increases satiety and improves glucose-dependent insulin signalling.
What still needs proving
The key question is whether the claimed benefit has been demonstrated in controlled human studies using the same compound, route and population.
What is it actually doing?
GLP-1 receptor agonist that slows gastric emptying, increases satiety and improves glucose-dependent insulin signalling.
The important distinction is between changing a biomarker or pathway and producing a meaningful outcome that people can feel, measure or sustain.
Results at a glanceHuman evidence
What did the studies actually find?
Human study deep dive
The most informative human evidence we could identify is translated below, with the original source linked.
Study evidenceStudy deep dives
The important studies, translated into normal English.
Each synopsis keeps the trial design, actual results and limitations together. Graphs below are redrawn from the cited numerical results so you can see the size of the effect without having to decode a journal figure.
STEP programme — semaglutide 2.4 mg
Large Phase 3 programme · adults with overweight/obesityAcross STEP 1, 3, 4 and 8, mean weight loss with 2.4 mg weekly was about 14.9%–17.4% at 68 weeks in adults without diabetes; STEP 5 reported −15.2% at 104 weeks versus −2.6% placebo.
This is mature large-scale human evidence, not an extrapolation from mechanism or anecdotes.
What it doesn't prove: Results depend on population, adherence and continued treatment; gastrointestinal adverse effects are common.
Read the original study / source ↗
Dosing referenceResearch, licensed & reported protocols
What doses and schedules are actually documented?
Human research or licensed product information is separated from clinic and community practice. These are source-attributed reference protocols, not personalised dosing recommendations.
Human research / licensed or product dosing
| Protocol / context | Amount & frequency | Duration | Titration | Evidence |
|---|---|---|---|---|
| Wegovy licensed start | 0.25 mg SC once weekly | Weeks 1–4 | Starting dose | FDA label |
| Wegovy escalation | 0.5 mg weeks 5–8 →1 mg weeks 9–12 →1.7 mg weeks 13–16 | 16-week escalation | Increase every 4 weeks | FDA label |
| Wegovy maintenance | 2.4 mg once weekly recommended; 1.7 mg once weekly is an adult maintenance option | Long-term | After escalation | FDA label |
| STEP 1 obesity trial | 2.4 mg once weekly after 16-week escalation | 68 weeks | 0.25→0.5→1→1.7→2.4 mg | Phase 3 RCT |
| STEP 6 | 1.7 mg or 2.4 mg weekly target arms | 68 weeks | Trial escalation | Phase 3a RCT |
Community / clinic / specialist protocols
| Pattern | Amount & frequency | Cycle | Progression | Status |
|---|---|---|---|---|
| Licensed-style community | 0.25 mg weekly start, then 4-week step-ups | Long-term | Usually mirrors product schedule | Community/clinical |
| Slower escalation | Hold a tolerated step longer than 4 weeks | Long-term | Delay increases rather than force monthly rise | Common real-world/clinic pattern |
| Lower-dose maintenance | Some community users remain below 2.4 mg | Long-term | Individualised; not the | Community |
| discussion | if response persists | labelled recommended obesity target |
Semaglutide has strong licensed and Phase-3 dosing evidence. PP should distinguish Wegovy obesity dosing from Ozempic diabetes dosing and should not call community 'microdosing' an evidence-based regimen.
Evidence checked: 7 October 2026
Routes and formulations matter. A topical study does not validate injection; an IV research dose does not establish a fixed SC dose; and evidence for one molecular form must not be silently transferred to another.
Community reportsCommunity reports
What are people actually doing?
Community experience exists, but is anecdotal
Forums discuss schedules, effects and side effects, but posts are uncontrolled self-reports and product identity may be uncertain. Use them to understand what people report—not to estimate efficacy or establish a dose.
View the discussion on Reddit ↗
Safety and uncertaintySafety, side effects & what we don't know
Established medicine with known gastrointestinal and other risks; product and indication matter.
Product identity, sterility and concentration are additional uncertainties for unlicensed research products. Evidence from an approved medicine or a clinical trial should not be transferred automatically to a differently sourced product.
QuestionsQuestions worth asking
What is the strongest evidence here?
This is mature large-scale human evidence, not an extrapolation from mechanism or anecdotes.
Does a biological mechanism prove the claimed benefit?
No. Receptor activity, cell effects and animal results can justify research, but controlled human outcomes are a separate evidential step.
Is the research protocol a recommended dose?
No. The site reports study protocols to explain the evidence. It does not turn them into personalised self-use instructions.
Primary sourcesStudies, sources & further reading
External links are provided for transparency and further reading. Linking to a study, discussion or organisation does not mean Peptides Peptalk endorses every conclusion on that page.